Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting -Secretase as an Alternative Drug Target for Treatment of Alzheimer's Disease

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|14|27|2848-2864

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.14, Iss.27, 2007-11, pp. : 2848-2864

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

γ-Secretase-Regulated Signaling: Notch, APP, and Alzheimer's Disease

By Nakayama Kohzo   Nagase Hisashi   Koh Chang-Sung   Ohkawara Takeshi  

Current Psychopharmacology, Vol. 1, Iss. 2, 2012-05 ,pp. : 155-166

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 5, 2016-02 ,pp. : 485-492

Bentham Science Publishers

Access to resources Recommend Favorite

Patents targeting γ-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004 – 2008

By Garofalo Albert W  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 7, 2008-07 ,pp. : 693-703

Informa Healthcare

Access to resources Recommend Favorite

Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases

By Heldin Carl-Henrik  

Journal of Neuroimmune Pharmacology, Vol. 9, Iss. 2, 2014-03 ,pp. : 69-79

Springer Publishing Company

Access to resources Recommend Favorite

&ggr;-Secretase as a Therapeutic Target for Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 12, Iss. 6, 2006-02 ,pp. : 661-670

Bentham Science Publishers

Access to resources Recommend Favorite